The role of high-dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma

D. A. Stewart, Julie Marie Vose, D. D. Weisenburger, J. R. Anderson, E. I. Ruby, M. A. Bast, Philip Jay Bierman, A. Kessinger, James Olen Armitage

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

Background: Although mantle cell lymphoma (MCL) is a distinct disease entity with well described clinical and pathological features, little information exists regarding its therapy. This paper will evaluate patients with MCLreceiving either induction therapy with an anthracycline or high-dose chemotherapy and autologous hematopoietic stem cell transplantation for relapsed disease.Patients and methods: The cases of 14 previously untreated patients with MCL who received an anthracycline-containing combination chemotherapy regimen on Nebraska Lymphoma Study Group protocols from 3/83 to 2/92 were reviewed. During the same time period, a different set of nine patients with recurrent MCL were referred for high-dose chemoradiotherapy and autologous stem cell rescue as salvage therapy.Results: The five year overall (OS) and failure-free (FFS) survivals from the initiation of chemotherapy for the patients receiving an induction therapy with an anthracycline containing regimen were 23% and 8%, respectively. At the time of this analysis, three of the nine transplant patients remain progression-free 7, 12, and 25 months post-transplant. Two year overall and FFS for all nine patients was 34%.Conclusions: Longer follow-up of greater patient numbers is required to determine whether high-dose therapy can overcome the chemoresistance and increase the cure rate of MCL. Since most patients with this disease have minimal chance of cure with standard chemotherapy, the optimal timing for high dose therapy may be as part of front-line treatment. Further clinical trials are required to investigate the potential benefits of high-dose therapy for patients with MCL.

Original languageEnglish (US)
Pages (from-to)263-266
Number of pages4
JournalAnnals of Oncology
Volume6
Issue number3
StatePublished - Mar 1 1995

Fingerprint

Mantle-Cell Lymphoma
Hematopoietic Stem Cell Transplantation
Anthracyclines
Therapeutics
Drug Therapy
Transplants
Salvage Therapy
Chemoradiotherapy
Combination Drug Therapy
Lymphoma
Stem Cells
Clinical Trials

Keywords

  • Hematopoietic stem cell transplantation
  • Mantle cell lymphoma

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

The role of high-dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma. / Stewart, D. A.; Vose, Julie Marie; Weisenburger, D. D.; Anderson, J. R.; Ruby, E. I.; Bast, M. A.; Bierman, Philip Jay; Kessinger, A.; Armitage, James Olen.

In: Annals of Oncology, Vol. 6, No. 3, 01.03.1995, p. 263-266.

Research output: Contribution to journalArticle

Stewart, DA, Vose, JM, Weisenburger, DD, Anderson, JR, Ruby, EI, Bast, MA, Bierman, PJ, Kessinger, A & Armitage, JO 1995, 'The role of high-dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma', Annals of Oncology, vol. 6, no. 3, pp. 263-266.
Stewart DA, Vose JM, Weisenburger DD, Anderson JR, Ruby EI, Bast MA et al. The role of high-dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Annals of Oncology. 1995 Mar 1;6(3):263-266.
Stewart, D. A. ; Vose, Julie Marie ; Weisenburger, D. D. ; Anderson, J. R. ; Ruby, E. I. ; Bast, M. A. ; Bierman, Philip Jay ; Kessinger, A. ; Armitage, James Olen. / The role of high-dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma. In: Annals of Oncology. 1995 ; Vol. 6, No. 3. pp. 263-266.
@article{630608ff7b0b47ed8621330327c6ed0b,
title = "The role of high-dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma",
abstract = "Background: Although mantle cell lymphoma (MCL) is a distinct disease entity with well described clinical and pathological features, little information exists regarding its therapy. This paper will evaluate patients with MCLreceiving either induction therapy with an anthracycline or high-dose chemotherapy and autologous hematopoietic stem cell transplantation for relapsed disease.Patients and methods: The cases of 14 previously untreated patients with MCL who received an anthracycline-containing combination chemotherapy regimen on Nebraska Lymphoma Study Group protocols from 3/83 to 2/92 were reviewed. During the same time period, a different set of nine patients with recurrent MCL were referred for high-dose chemoradiotherapy and autologous stem cell rescue as salvage therapy.Results: The five year overall (OS) and failure-free (FFS) survivals from the initiation of chemotherapy for the patients receiving an induction therapy with an anthracycline containing regimen were 23{\%} and 8{\%}, respectively. At the time of this analysis, three of the nine transplant patients remain progression-free 7, 12, and 25 months post-transplant. Two year overall and FFS for all nine patients was 34{\%}.Conclusions: Longer follow-up of greater patient numbers is required to determine whether high-dose therapy can overcome the chemoresistance and increase the cure rate of MCL. Since most patients with this disease have minimal chance of cure with standard chemotherapy, the optimal timing for high dose therapy may be as part of front-line treatment. Further clinical trials are required to investigate the potential benefits of high-dose therapy for patients with MCL.",
keywords = "Hematopoietic stem cell transplantation, Mantle cell lymphoma",
author = "Stewart, {D. A.} and Vose, {Julie Marie} and Weisenburger, {D. D.} and Anderson, {J. R.} and Ruby, {E. I.} and Bast, {M. A.} and Bierman, {Philip Jay} and A. Kessinger and Armitage, {James Olen}",
year = "1995",
month = "3",
day = "1",
language = "English (US)",
volume = "6",
pages = "263--266",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - The role of high-dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma

AU - Stewart, D. A.

AU - Vose, Julie Marie

AU - Weisenburger, D. D.

AU - Anderson, J. R.

AU - Ruby, E. I.

AU - Bast, M. A.

AU - Bierman, Philip Jay

AU - Kessinger, A.

AU - Armitage, James Olen

PY - 1995/3/1

Y1 - 1995/3/1

N2 - Background: Although mantle cell lymphoma (MCL) is a distinct disease entity with well described clinical and pathological features, little information exists regarding its therapy. This paper will evaluate patients with MCLreceiving either induction therapy with an anthracycline or high-dose chemotherapy and autologous hematopoietic stem cell transplantation for relapsed disease.Patients and methods: The cases of 14 previously untreated patients with MCL who received an anthracycline-containing combination chemotherapy regimen on Nebraska Lymphoma Study Group protocols from 3/83 to 2/92 were reviewed. During the same time period, a different set of nine patients with recurrent MCL were referred for high-dose chemoradiotherapy and autologous stem cell rescue as salvage therapy.Results: The five year overall (OS) and failure-free (FFS) survivals from the initiation of chemotherapy for the patients receiving an induction therapy with an anthracycline containing regimen were 23% and 8%, respectively. At the time of this analysis, three of the nine transplant patients remain progression-free 7, 12, and 25 months post-transplant. Two year overall and FFS for all nine patients was 34%.Conclusions: Longer follow-up of greater patient numbers is required to determine whether high-dose therapy can overcome the chemoresistance and increase the cure rate of MCL. Since most patients with this disease have minimal chance of cure with standard chemotherapy, the optimal timing for high dose therapy may be as part of front-line treatment. Further clinical trials are required to investigate the potential benefits of high-dose therapy for patients with MCL.

AB - Background: Although mantle cell lymphoma (MCL) is a distinct disease entity with well described clinical and pathological features, little information exists regarding its therapy. This paper will evaluate patients with MCLreceiving either induction therapy with an anthracycline or high-dose chemotherapy and autologous hematopoietic stem cell transplantation for relapsed disease.Patients and methods: The cases of 14 previously untreated patients with MCL who received an anthracycline-containing combination chemotherapy regimen on Nebraska Lymphoma Study Group protocols from 3/83 to 2/92 were reviewed. During the same time period, a different set of nine patients with recurrent MCL were referred for high-dose chemoradiotherapy and autologous stem cell rescue as salvage therapy.Results: The five year overall (OS) and failure-free (FFS) survivals from the initiation of chemotherapy for the patients receiving an induction therapy with an anthracycline containing regimen were 23% and 8%, respectively. At the time of this analysis, three of the nine transplant patients remain progression-free 7, 12, and 25 months post-transplant. Two year overall and FFS for all nine patients was 34%.Conclusions: Longer follow-up of greater patient numbers is required to determine whether high-dose therapy can overcome the chemoresistance and increase the cure rate of MCL. Since most patients with this disease have minimal chance of cure with standard chemotherapy, the optimal timing for high dose therapy may be as part of front-line treatment. Further clinical trials are required to investigate the potential benefits of high-dose therapy for patients with MCL.

KW - Hematopoietic stem cell transplantation

KW - Mantle cell lymphoma

UR - http://www.scopus.com/inward/record.url?scp=0028950965&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028950965&partnerID=8YFLogxK

M3 - Article

C2 - 7612492

AN - SCOPUS:0028950965

VL - 6

SP - 263

EP - 266

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 3

ER -